MedTrace Logo

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

NCT05322330 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-02-09

No results posted yet for this study

Summary

Aim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma

Conditions

  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

Selinexor

40-60mg QW,w-3～d-3,PO

DRUG

Flu

25-30 mg/m2，d-5 ～d-3，qd，ivgtt

DRUG

CTX

250-500 mg/m2，d-5 ～d-3，qd，ivgtt

DRUG

CAR-T

2-5×10\^6 CAR-T/kg，ivgtt。

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • The General Hospital of Western Theater Command

    collaborator OTHER

  • The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community

    collaborator UNKNOWN

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Yixing People's Hospital

    collaborator OTHER

  • Affiliated Hospital of Jiangnan University

    collaborator OTHER

  • Wuxi No. 2 People's Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Depei Wu, M.D · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2024-02-10
Completion
2024-02-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322330 on ClinicalTrials.gov